HCC	Hepatocellular carcinoma;
LOXL2	Lysyloxidase-like 2;
HBV	Hepatitis B virus;
HCV	Hepatitis C virus;
MASLD	Metabolic dysfunction-associated steatotic liver disease;
TACE	Transarterialchemoembolization;
VEGF	Vascular endothelial growth factor;
TME	Tumor microenvironment;
CAF	Cancer-associated fibroblasts;
ECM	Extracellular matrix;
LTQ	Lysine tyrosylquinone;
ELN	Elastin;
FBLN5	Fibulin-5;
PCOLCE	Procollagen C-endopeptidase enhancer 1;
TLL1	Tolloid-like protein 1;
BMP	Bone morphogenic protein 1;
CAIX	Carbon anhydrase IX;
HSC	Hepatic stellate cells;
BMDC	Bone marrow-derived cells;
TGF-ß	Transforming growth factor-beta;
HIF-1α	Hypoxia-inducible factor 1 alpha;
JNK-c	Jun N-terminal kinase;
5FU	5-fluorouracil;
FAK	Focaladhesion kinase;
ROCK	Rho-associated protein kinase;
CCL5	Chemokine ligand 5;
ZEB1	Zinc finger E-box-binding homeobox 1;
MEK1/2	Mitogen-activated protein kinase 1/2;
ERK 1/2	Extracellular signal-regulated kinase 1/2;
MMP	Matrix metalloproteinase
HRE	Hypoxia responsive element;
FBP1	Fructose-1,6-biphosphatase protein 1;
PDGFRß	Platelet-derived growth factor receptor beta;
miR	micro-RNA;
BAPN	ß-aminopropionitrile.